LB Pharmaceuticals (NASDAQ: LBRX) director to retire and serve as consultant

Did LB Pharmaceuticals report any disagreement with Zachary Prensky related to his retirement?

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

What board change did LB Pharmaceuticals Inc (LBRX) disclose?

Why is LB Pharmaceuticals director Zachary Prensky leaving the board?

Will Zachary Prensky continue working with LB Pharmaceuticals (LBRX) after retiring from the board?

How does the transition agreement amendment affect Zachary Prensky’s equity with LB Pharmaceuticals?

Where can investors find the full text of Zachary Prensky’s Transition Agreement Amendment with LB Pharmaceuticals?

No. LB Pharmaceuticals specifically stated that Zachary Prensky’s decision to retire from the Board was not the result of any disagreement with the company regarding its operations, policies, or practices, indicating an orderly and cooperative transition.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

LB Pharmaceuticals Inc reported that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His current term will end at the conclusion of that meeting, and he will continue serving on the Board and the Nominating and Corporate Governance Committee until then.

The company stated that Mr. Prensky’s decision was not due to any disagreement regarding operations, policies, or practices. After his Board service ends, he is expected to provide consulting services under an amended Transition, Separation, and Consulting Agreement, which allows his unvested stock options to continue vesting during the agreement term.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

03/16/2026 - 04:40 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware

001-42831

81-1854347

(State of

incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)


One Pennsylvania Plaza, Suite 1025
New York, NY				10119
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

LBRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Director

On March 13, 2026, Zachary Prensky notified the Board of Directors (the “Board”) of LB Pharmaceuticals Inc (the “Company”) of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Mr. Prensky’s term as a director will end when his current term expires at the 2026 Annual Meeting. Mr. Prensky will remain as a member of the Board and as a member of the Nominating and Corporate Governance Committee of the Board until the conclusion of the 2026 Annual Meeting.

Mr. Prensky’s decision to resign was not a result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices. Following his resignation date, Mr. Prensky is expected to provide consulting services to the Company. The Board thanks Mr. Prensky for his years of service and valuable contributions to the Company.

In connection with Mr. Prensky’s separation from the Company, the Company and Mr. Prensky entered into an Amendment No. 1 to Transition, Separation, and Consulting Agreement (the “Transition Agreement Amendment”), effective June 3, 2026, which amended that certain Transition, Separation, and Consulting Agreement, dated November 26, 2024 (the “Transition Agreement”). Pursuant to the Transition Agreement Amendment, Mr. Prensky will continue to provide consulting services as may be reasonably requested by the Company and receive the benefits described in the Transition Agreement. In addition, Mr. Prensky’s outstanding and unvested stock options are eligible to continue to vest for the duration of the term of the Transition Agreement Amendment.

The foregoing description is a summary of the Transition Agreement Amendment and is qualified in its entirety by reference to the full text of the Transition Agreement Amendment, a copy of which will be filed as exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

LB Pharmaceuticals disclosed that director Zachary Prensky plans to retire from the Board at the 2026 annual meeting. He will serve out his current term and remain on the Nominating and Corporate Governance Committee until the meeting concludes.

The company stated that Zachary Prensky is retiring and will not stand for reelection at the 2026 annual meeting. His decision was expressly noted as not resulting from any disagreement over LB Pharmaceuticals’ operations, policies, or practices.

Yes. Following his retirement from the Board at the 2026 annual meeting, Zachary Prensky is expected to continue providing consulting services to LB Pharmaceuticals under an amended Transition, Separation, and Consulting Agreement.

Under the Transition Agreement Amendment, Zachary Prensky’s outstanding and unvested stock options are eligible to continue vesting for the duration of the amended agreement term, while he provides consulting services as reasonably requested by the company.

The company indicated that the full text of the Transition Agreement Amendment will be filed as an exhibit to LB Pharmaceuticals’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, providing complete contractual details.

LB Pharmaceuticals Inc

Date: March 16, 2026

/s/ Heather Turner

Heather Turner

Chief Executive Officer

3 documents